TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10793229
Drug: Oral casokefamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral casokefamide at doses of 5.5, 8.0, and 16.0 mg
Study: 10793229
Drug: Oral casokefamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral casokefamide
Study: 1993412
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Timentin (3.1 g IV at commencement of operation)
Study: 1993412
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of Timentin (3.1 g IV at commencement of operation and repeated after 2 hours)
Study: 1993412
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Timentin
Study: 1993412
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of Timentin
Study: 30946377
Drug: BiOSS LIM
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BiOSS LIM C stent (dedicated bifurcation balloon expandable stent made of cobalt‐chromium alloy, releasing sirolimus 1.4 μg/mm)
Study: 30946377
Drug: limus second‐generation
Approvals — FDA: no, EMA: no, PMDA: no
Description: limus second‐generation drug‐eluting stents (DES)
Study: 30680523
Drug: Aprepitant (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (125 mg on day 1 and 80 mg on days 2-3)
Study: 26588232
Drug: Fosaprepitant (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant (150 mg, day 1)
Study: 24823715
Drug: Bolus dose
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dose of 1.0 μg·kg(‐1) dexmedetomidine followed by a continuous infusion of 0.5 μg·kg(‐1) ·h(‐1) (group D1)
Study: 24823715
Drug: Bolus dose
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dose of 2.0 μg·kg(‐1) dexmedetomidine followed by a continuous infusion of 1.0 μg·kg(‐1) ·h(‐1) (group D2)
Study: 11779598
Drug: Metformin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin therapy (850 mg, twice daily)
Study: 11779598
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate induction (100 mg/day on cycle days 3‐7 of the second cycle) with Metformin
Study: 11779598
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (twice daily)
Study: 9828903
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose testosterone treatment (100 mg subcutaneous implants every six months for at least two years, mean duration 3.3 ± 0.9 years)
Study: 8016878
Drug: OG 37‐325
Approvals — FDA: no, EMA: no, PMDA: no
Description: OG 37‐325 (nva‐cyclosporine, cyclosporine G)
Study: 2816609
Drug: HLBI monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLBI monotherapy (3 million units daily for 4 days, then twice weekly)
Study: 2816609
Drug: Combined HLBI
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined HLBI with 5-FU (300 or 600 mg orally)
Study: 2816609
Drug: Either HLBI
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either HLBI treatment (monotherapy or combined)
Study: 776840
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (CTX, vincristine, and methotrexate - COM)
Study: 6102627
Drug: Clavulanic acid
Normalized name: Clavulanic acid
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clavulanic acid in combination with amoxycillin
Study: 17593865
Drug: HFA-BDP (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-BDP (200 microg once daily)
Study: 17593865
Drug: BUD-TH (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD-TH (400 microg twice daily)
Study: 17593865
Drug: FP-IH (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP-IH (250 microg twice daily)
Study: 12374629
Drug: clomipramine+lithium (C+L)
Approvals — FDA: no, EMA: no, PMDA: no
Description: clomipramine+lithium (C+L)
Study: 10357419
Drug: 3D-CRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D-CRT with a minimum tumor dose of 64.8 Gy to 81.0 Gy
Study: 8596484
Drug: Cephalic-phase insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cephalic-phase insulin response (CPIR) before weight reduction
Study: 8596484
Drug: Cephalic-phase insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cephalic-phase insulin response (CPIR) after weight reduction
Study: 8596484
Drug: First-phase insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-phase insulin secretion during intravenous glucose tolerance test (IVGTT)
Study: 1763606
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta-estradiol
Study: 6121965
Drug: Methyldopa treatment
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa treatment during pregnancy
Study: 6794796
Drug: Methyldopa treatment
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa treatment
Study: 30346340
Drug: Impression Cytology
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Impression Cytology using EYEPRIM device with topical anesthesia
Study: 30346340
Drug: Impression Cytology
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Impression Cytology using EYEPRIM device without topical anesthesia
Study: 24945194
Drug: Thalidomide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (100 mg once daily for 3 months)
Study: 24945194
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching oral placebo for 3 months)
Study: 24945194
Drug: Thalidomide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (100 mg to 200 mg daily for 3 months, open-label follow-up)
Study: 21052881
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg before surgery and 150 mg every 8 hours
Study: 21052881
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 550 mg before surgery and 550 mg every 12 hours
Study: 17107734
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy (IFN-alpha)
Study: 2288141
Drug: ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ursodeoxycholic acid 500 mg once a day
Study: 31529104
Drug: Nonopioid medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonopioid medication therapy
Study: 26685082
Drug: Physician-family communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-family communication ratings (answering family's questions, listening to family, asking about treatments patient would want, helping family decide patient's treatment wishes, overall communication)
Study: 27881132
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 200 μg
Study: 21828231
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 400 μg
Study: 21828231
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 600 μg
Study: 21828231
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 800 μg
Study: 21828231
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 500 μg
Study: 18278078
Drug: Cholesterol-lowering medication,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering medication, percutaneous coronary intervention, and coronary artery bypass surgery
Study: 2258635
Drug: recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant interferon alpha‐2b (rIFN alpha 2b) therapy for a total period of 20 months
Study: 28408798
Drug: Low-dose SKA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose SKA cytokines (IL-4, IL-10, anti-IL-1 antibodies at 10 fg/mL, orally administered at a dose of 20 drops/d for 12 months)
Study: 28408798
Drug: Disease-modifying antirheumatic
Normalized name: ANTIRHEUMATICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying antirheumatic drugs (DMARDs) therapy
Study: 25942722
Drug: NTCD-M3 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTCD-M3 (all doses combined)
Study: 19127172
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (fluoxetine + cognitive-behavioral therapy)
Study: 19127172
Drug: Overall (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall (all active treatments)
Study: 18688944
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg)
Study: 15318251
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (4 ml/kg, 1.8 meq/kg)
Study: 11289198
Drug: Enhanced therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced therapy for early syphilis
Study: 11289198
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for early syphilis
Study: 9260006
Drug: Multimodal pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal pain treatment with intrathecal morphine, incisional bupivacaine and ibuprofen+acetaminophen po until hospital discharge (Group 1)
Study: 9260006
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with iv PCA morphine weaned to acetaminophen+codeine po (Group 2)
Study: 30861167
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education
Study: 21933100
Drug: Omalizumab (OMA)
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab (OMA) added to optimized asthma therapy (OAT) for 32 weeks
Study: 21933100
Drug: Optimized asthma
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optimized asthma therapy (OAT) alone for 32 weeks
Study: 10766183
Drug: GM‐CSF in
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF in combination with IL‐4 (0.5‐6.0 microg/kg/day)
Study: 10766183
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (GM‐CSF and IL‐4)
Study: 2361891
Drug: Placebo (dextrose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dextrose, 5 mg/kg)
Study: 22805286
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea polyphenols (GTP) 640 mg
Study: 19769480
Drug: Menoprogen (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menoprogen (0.2 g extracts of five herbs per capsule, two capsules orally, twice daily)
Study: 15345867
Drug: Fat-modified diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-modified diet (SFA < 10%, MUFA 10-5%, PUFA up to 10%, cholesterol < 300 mg/day)
Study: 11393673
Drug: Isradipine 5
Normalized name: isradipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 5 mg/day
Study: 19453311
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron
Study: 9065130
Drug: Intravenous promethazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous promethazine
Study: 2680157
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (type 1)
Study: 2680157
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (type 1)
Study: 2680157
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (type 2)
Study: 2680157
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (type 2)
Study: 2680157
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (lowest ejection fraction tercile)
Study: 2680157
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (lowest ejection fraction tercile)
Study: 146916
Drug: Topical retinoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinoic acid
Study: 26046102
Drug: Probiotic yogurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yogurt containing Bifidobacterium lactis (1×10(6) per gram), 200g once daily for 2 weeks
Study: 19325490
Drug: Rivastigmine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (3 doses of 1.5 mg per day starting the evening before surgery until the evening of the sixth postoperative day)
Study: 15448038
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of zoledronic acid
Study: 9069483
Drug: Active warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active warfarin and active aspirin
Study: 9069483
Drug: Active warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active warfarin and placebo aspirin
Study: 9069483
Drug: Placebo warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo warfarin and active aspirin
Study: 29929169
Drug: IV PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV PCA + posterior QLB with 0.3 ml/kg 0.25% bupivacaine
Study: 29929169
Drug: IV PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV PCA + posterior QLB with 0.3 ml/kg 0.9% saline
Study: 24929235
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of emtricitabine and TDF (FTC/TDF)
Study: 29143869
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg
Study: 3440636
Drug: Ketanserin 20
Normalized name: ketanserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 20 mg
Study: 17205319
Drug: Haloperidol 3
Normalized name: Haloperidol 300 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 3 mg
Study: 2149042
Drug: Teicoplanin at
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin at a dose of 400 mg/d
Study: 82086
Drug: Cimetidine 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1.6 g daily for 6 weeks
Study: 1632401
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor
Study: 16923922
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II type 1 receptor antagonist
Study: 16923922
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Angiotensin-converting enzyme inhibitor + Angiotensin II type 1 receptor antagonist)
Study: 15217999
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg daily from day 3-7 and recombinant FSH (rFSH) 75 IU/day on days 3 and 8
Study: 15217999
Drug: Long GnRH
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long GnRH agonist protocol and stimulated with rFSH (300-450 IU/day)
Study: 11526368
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (AADs) - primarily amiodarone
Study: 3306748
Drug: Caffeine 240
Normalized name: aspirin/acetaminophen/caffeine 240 mg-125 mg-32 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 240 mg
Study: 3306748
Drug: Caffeine 480
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 480 mg
Study: 3306748
Drug: Caffeine 720
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine 720 mg
Study: 28744796
Drug: ABT-122 (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-122 (0.1, 0.3, 1, 3, and 10 mg/kg intravenous; 0.3, 1, and 3 mg/kg subcutaneous)
Study: 28744796
Drug: ABT-122 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-122 (1 mg/kg every other week or 0.5-3 mg/kg every week for 8 weeks)
Study: 28744796
Drug: ABT-122 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-122 (1 mg/kg every other week)
Study: 28744796
Drug: ABT-122 (0.5-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-122 (0.5-3 mg/kg every week)
Study: 28744796
Drug: ABT-122 (every
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-122 (every week dosing)
Study: 27053384
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (3 times daily 117 mg or 350 mg/d)
Study: 20861645
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus L-92
Study: 20079899
Drug: metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin (500 mg three times a day) plus simvastatin (20 mg/day)
Study: 20079899
Drug: metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin (500 mg three times a day) plus placebo
Study: 18462468
Drug: NTrainer treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTrainer treatment provided to 21 infants.
Study: 18462468
Drug: NTrainer treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTrainer treatment
Study: 15998657
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (400 IU/day of vitamin E, 500 mg/day of vitamin C, 6 mg/day of beta-carotene)
Study: 8734674
Drug: Once-daily aminoglycosides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily aminoglycosides
Study: 6343340
Drug: Oral fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fenoterol 0.8 mg/kg in three divided doses
Study: 6343340
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol (higher than 0.4 mg three times per day)
Study: 28002165
Drug: High-sensitivity cardiac
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity cardiac troponin T (hs-cTnT) >14 ng/L and NT-proBNP >300 ng/L
Study: 28002165
Drug: NT-proBNP cutoff
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP cutoff at 108 ng/L
Study: 25770644
Drug: KETODEX (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: KETODEX (low-dose ketamine 0.15 mg/kg followed by dexmedetomidine 0.3 μg/kg i.v.)
Study: 18679038
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment for 6 weeks
Study: 10826241
Drug: Behavioral Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Family Systems Therapy (BFST)
Study: 3921278
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diltiazem and propranolol
Study: 29206720
Drug: HIV prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV prevention intervention providing 80% reduction in susceptibility per act; specific dosage and duration not mentioned.
Study: 28770449
Drug: 30,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30,000 IU oral VitD3/week
Study: 26791798
Drug: pemetrexed +
Approvals — FDA: no, EMA: no, PMDA: no
Description: pemetrexed + cisplatin (500 mg/m² + 75 mg/m²)
Study: 26791798
Drug: pemetrexed +
Approvals — FDA: no, EMA: no, PMDA: no
Description: pemetrexed + carboplatin (500 mg/m² + AUC5)
Study: 22024529
Drug: Opened capsule
Normalized name: naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opened capsule dosing method (30 mg)
Study: 22024529
Drug: Intact capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact capsule dosing method (30 mg)
Study: 12420014
Drug: Intra-oral lubricating
Normalized name: Eyes Alive Lubricating
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-oral lubricating device
Study: 13678775
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg i.v. neridronate bimonthly and 500 mg calcium plus 400 U vitamin D supplements daily (n=39)
Study: 13678775
Drug: Calcium-vitamin D
Normalized name: Calcium-Vitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-vitamin D supplements alone (control group, n=39)
Study: 10916115
Drug: Lisinopril 10
Normalized name: lisinopril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10 mg/day (group A)
Study: 8956382
Drug: Ritanserin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin 2.5 mg/day or 5 mg/day
Study: 1388038
Drug: Clodronate 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 300 mg/day plus hydration
Study: 27482970
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg esmirtazapine